Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs

Wang,Yuqian; Liu,Chenlu; Xia,Qiu; Wang,Peng; Li,Bo; Lu,Zhenzhen; Sun,Jiaxi; Wu,Hui; Yu,Bin; Wu,Jiaxin; Yu,Xianghui; Kong,Wei; Zhang,Haihong; Cong,Xianling

doi:10.3892/or.2013.2950

Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs

Authors:
- Yuqian Wang
- Chenlu Liu
- Qiu Xia
- Peng Wang
- Bo Li
- Zhenzhen Lu
- Jiaxi Sun
- Hui Wu
- Bin Yu
- Jiaxin Wu
- Xianghui Yu
- Wei Kong
- Haihong Zhang
- Xianling Cong
View Affiliations

Affiliations: Science Research Center, China-Japan Union Hospital, Jilin University, Changchun 130012, P.R. China, National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun 130012, P.R. China, High School affiliated with Jilin University, Changchun 130012, P.R. China
Published online on: December 30, 2013 https://doi.org/10.3892/or.2013.2950
Pages: 1437-1444

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucin 1 (MUC1) is a tumor-associated antigen that is overexpressed in several adenocarcinomas. However, clinical trials with MUC1 showed that MUC1 is a relatively poor immunogen in humans. In view of the low immunogenicity of this protein vaccine, we designed a method based on an immunoadjuvant and immunization strategy to enhance the cellular immune response to this protein vaccine. DDA/MPL has been evaluated as an adjuvant to induce strong immunity for the tuberculosis vaccine. However, its adjuvant role combined with the vaccine targeting MUC1 in malignant carcinomas has not previously been reported. Our previous study showed that adenovirus prime protein boost vaccination could significantly enhance the cellular immunity and antitumor efficacy. In our study, we used MUC1 VNTRs as the target of cancer vaccine and DDA/MPL as the adjuvant to enhancing the cellular immunity of recombinant MUC1 protein vaccine, and an AD-9M adenoviral vector prime-recombinant protein and DDA/MPL boost (designated MUC-1 VPP vaccine) strategy was studied to enhance the antitumor efficacy. The results demonstrated that antigen-specific IFN-γ-secreting T cells were increased by 2-fold, and cytotoxic T lymphocytes (CTLs) were induced effectively when the protein vaccine was combined with the DDA/MPL adjuvant. Moreover, the vaccination induced nearly 60% inhibition of the growth of B16 melanoma in mice and prolonged the survival of tumor-bearing mice. The inhibition was correlated with the specific immune responses induced by the MUC1 VPP vaccine. The data suggested that DDA/MPL-adjuvant MUC-1 VPP vaccine may be developed into effective tumor vaccines for melanomas and possibly for other tumors expressing MUC1 protein.

View Figures

View References

1	Tang CK and Apostolopoulos V: Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines. 7:951–962. 2008. View Article : Google Scholar : PubMed/NCBI
2	Tang CK, Katsara M and Apostolopoulos V: Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines. 7:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
3	Snyder LA, Goletz TJ, Gunn GR, et al: A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine. 24:3340–3352. 2006. View Article : Google Scholar : PubMed/NCBI
4	Tarp MA, Sorensen AL, Mandel U, et al: Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology. 17:197–209. 2007. View Article : Google Scholar : PubMed/NCBI
5	Yuan S, Shi C, Lv Y, Wang T, Wang H and Han W: A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm. 24:607–613. 2009.PubMed/NCBI
6	Mukherjee P, Basu GD, Tinder TL, et al: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol. 182:216–224. 2009. View Article : Google Scholar : PubMed/NCBI
7	Nicholls EF, Madera L and Hancock RE: Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann NY Acad Sci. 1213:46–61. 2010. View Article : Google Scholar : PubMed/NCBI
8	Korsholm KS, Agger EM, Foged C, et al: The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology. 121:216–226. 2007. View Article : Google Scholar : PubMed/NCBI
9	Persing DH, Coler RN, Lacy MJ, et al: Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:S32–S37. 2002. View Article : Google Scholar : PubMed/NCBI
10	Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 11:443–451. 1999. View Article : Google Scholar : PubMed/NCBI
11	Wang YQ, Zhang HH, Liu CL, et al: Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol. 17:9–17. 2013. View Article : Google Scholar : PubMed/NCBI
12	Harari A, Bart PA, Stohr W, et al: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 205:63–77. 2008. View Article : Google Scholar : PubMed/NCBI
13	Magalhaes I, Sizemore DR, Ahmed RK, et al: rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One. 3:e37902008. View Article : Google Scholar : PubMed/NCBI
14	Garcia-Hernandez Mde L, Gray A, Hubby B and Kast WM: In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 67:1344–1351. 2007.PubMed/NCBI
15	Yu B, Zhang Y, Zhan Y, et al: Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep. 26:255–264. 2011.PubMed/NCBI
16	You Q, Jiang C, Wu Y, et al: Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol. 75:77–84. 2012. View Article : Google Scholar
17	Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P and Brunham RC: Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun. 80:1510–1518. 2012. View Article : Google Scholar
18	Kolibab K, Parra M, Yang AL, Perera LP, Derrick SC and Morris SL: A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine. 28:317–322. 2009. View Article : Google Scholar : PubMed/NCBI
19	de Gruijl TD and van de Ven R: Chapter six - Adenovirus-based immunotherapy of cancer: promises to keep. Adv Cancer Res. 115:147–220. 2012.PubMed/NCBI
20	Cheever MA, Allison JP, Ferris AS, et al: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lu S: Heterologous prime-boost vaccination. Curr Opin Immunol. 21:346–351. 2009. View Article : Google Scholar